BHC Insider Trading
Insider Ownership Percentage: 8.12%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $83,027.70
Bausch Health Companies Insider Trading History Chart
This chart shows the insider buying and selling history at Bausch Health Companies by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Bausch Health Companies Share Price & Price History
Current Price: $6.88
Price Change: ▲ Price Increase of +0.085 (1.25%)
As of 03/13/2025 04:58 PM ET
Bausch Health Companies Insider Trading History
SEC Filings (Institutional Ownership Changes) for Bausch Health Companies (NYSE:BHC)
78.65% of Bausch Health Companies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at BHC by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Bausch Health Companies Institutional Trading History
Data available starting January 2016
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Read More on Bausch Health Companies
Volume
1,204,030 shs
Average Volume
2,692,772 shs
Market Capitalization
$2.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.59
Who are the company insiders with the largest holdings of Bausch Health Companies?
Who are the major institutional investors of Bausch Health Companies?
Which major investors are selling Bausch Health Companies stock?
Within the previous quarter, BHC stock was sold by these institutional investors:
- Bank of Montreal Can
- Wolverine Trading LLC
- PointState Capital LP
- Deutsche Bank AG
- Laurion Capital Management LP
- Diameter Capital Partners LP
- Lighthouse Investment Partners LLC
- Citadel Advisors LLC
Which major investors are buying Bausch Health Companies stock?
Within the previous quarter, BHC stock was bought by institutional investors including:
- Maple Rock Capital Partners Inc.
- Compass Rose Asset Management LP
- Arrowstreet Capital Limited Partnership
- SG Americas Securities LLC
- O Shaughnessy Asset Management LLC
- Renaissance Technologies LLC
- Bridgewater Associates LP
- Vestal Point Capital LP